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Patients with common variable immunodeficiency (CVID) have impaired production of immu-
noglobulins and hence recurrent airway infections, which in turn may lead to radiological
changes and impaired lung function. Uncertainty exists about the nature and frequency of
the radiological and the physiological abnormalities, and how they relate to each other. We
reassessed high resolution computed tomography (HRCT) images in 65 patients, reported
results from previously measured lung function tests, and studied relations between radiology,
function and clinical variables. Airway obstruction, ventilatory restriction and impaired gas
diffusion was found in 40, 34 and 21% of the patients, respectively. HRCT abnormalities were
present in 94% of the subjects, mild changes being the most common. Bronchial wall thick-
ening, found in two thirds of the patients, was related to airway obstruction and impaired
gas diffusion. Linear and/or irregular opacities, the most frequent interstitial abnormality,
was related to impaired gas diffusion. Bronchiectasis was found in more than half, but only
severe bronchiectasis was related to airway obstruction. Since bronchial wall thickening and
linear and/or irregular opacities are both frequent and important determinants of impaired
pulmonary function, more attention should be given to these features in the follow up of CVID
patients.
ª 2008 Elsevier Ltd. All rights reserved.56 7219; fax: þ47 2307 3917.
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Common variable immunodeficiency (CVID) is a primary
immunodeficiency disease characterised by impaired
production of immunoglobulins and recurrent airway.
Patients with
CVID followed
at our clinic
92
Patient records
screened
85
Patients with PFT
83
Patients with
PFT and HRCT in
<13 months
70
Patient record or
PFT not found
7 
PFT not performed
2
Number of
patients
Causes of
exclusion
Patients in
the study
65 
Acute infection
5
HRCT not performed
6
>13 months between
PFT and HRCT
7
HRCT = High resolution computed tomography
PFT = Pulmonary function test
874 S. Gregersen et al.infections, which in turn may lead to chronic pulmonary
damage. T cell and macrophage/monocyte abnormalities
are also common and likely contribute to the increased
incidence of autoimmune diseases seen in these
patients.1
Bronchiectasis, a frequent finding on high resolution CT
(HRCT) in CVID, is usually accompanied by airflow limitation
and is probably the cause of daily cough and sputum.2,3
Non-infectious pulmonary manifestations such as granulo-
matous and lymphoproliferative disorders (e.g. lymphocytic
interstitial pneumonia and organising pneumonias), often
visualised as HRCT abnormalities of the lung interstitium,
may lead to reduced lung volumes and gas diffusion.4,5 The
pathogenesis of the pulmonary damage in CVID is not clear,
but probably complex.
Reports from previous studies of HRCT in CVID reveal
that there is no complete agreement on which abnormali-
ties to be assessed.5e7 As a consequence, uncertainty exists
about the nature and occurrence of CT abnormalities in
CVID, and how these relate to pulmonary function. The
majority of the diagnosed CVID patients in Norway has
a regularly follow up at our clinic, Rikshospitalet University
Hospital, which is a reference hospital for adult patients
with primary immunodeficiency syndromes in Norway.8 The
follow up includes pulmonary function tests and HRCT
annually or every 2nd year. IgG replacement therapy in our
patients includes subcutaneous (SCIG) or intravenous
(IVIG), or both.9,10
The objectives of the present study were to examine the
nature and frequency of radiological abnormalities and
their relations to pulmonary function in a relatively large
group of patients with CVID.Figure 1 Float diagram showing procedure for selection of
the final study group.Patients and methods
Patient selection
In this retrospective, cross sectional study, 92 patients with
CVID who were or had been followed at our hospital up to
2004, were initially included. These constituted approxi-
mately 80% of the Norwegian CVID patients.8
The diagnosis of CVID was in accordance with WHO
diagnostic criteria11 with serum levels of at least two of the
three Ig isotypes (IgG, IgA, IgM) two standard deviations or
more below mean of the age, onset of immunodeficiency at
greater than 2 years of age, and other causes of hypo-
gammaglobulinemia having been excluded. The float
diagram in Fig. 1 shows the procedure for selection of the
final study group of 65. These patients (29 women and 36
men), had performed both pulmonary function tests (PFT)
and HRCT within a short time span (median 0, range 0e
13 months). Patients who had used antibiotics were
included if they had stopped at least 1 week before PFT or
HRCT examination. Information about demographic and
clinical data was extracted from the patient records.Pulmonary function tests (PFT)
PFT’s had been performed on a Vmax Pulmonary Function
Unit (ViaSys, Santa Ana, CA, USA) in accordance withERS guidelines.12 Pulmonary function variables included
forced vital capacity (FVC), forced expiratory volume in
1 s (FEV1), and FEV1/FVC. Diffusing capacity (DLCO),
adjusted for haemoglobin, and alveolar volume (VA), had
been measured with the single breath carbon monoxide
test. VA was taken as a substitute for total lung capacity
(TLC). The predicted values were those of ERS 1993
update.12
High resolution computed tomography
The HRCT examinations had been carried out as routine
investigations, with a HiSpeed CT/i scanner (GE Medical
Systems, Milwaukee, WI, USA). The images were obtained
at 120 kV and 200e240 mA with 1 mm collimation at 10 mm
interval and reconstructed with a high-spatial-frequency
(bone) algorithm. If inspiratory scans showed signs of
airway disease, expiratory scans were performed. This was
the case in 54 patients. Readings were performed in
consensus on a picture archiving and communication system
(PACS) screen by two experienced chest radiologists (TMA
and GM) without prior knowledge of patient history or lung
function. In cases where the two radiologists disagreed,
a third was consulted. One half of the images were assessed
Table 1 Clinical characteristics in 65 patients with CVID.
Variable Number of
patients
%
Splenomegalya 30 46
Granulomatous diseaseb 7 11
Haematological abnormalitiesc 24 37
Other autoimmune diseased 28 43
Gastrointestinal symptomse 28 43
Productive cough
Males 20 30
Females 8 12
>2 bacterial infections last year 21 32
Daily or current smoking 27 41
Inhaled steroids 14 22
Beta2agonist 20 30
a Length >13 cm on ultrasound or CT examination. Includes
spleenectomised.
b Non-caseating granulomata in various tissue biopsies.
c E.g. neutropenia, anemia, thrombocytopenia.
d E.g. arthritis, thyroiditis.
e E.g. mal absorption, diarrhoea.
HRCT and lung function in CVID 875twice, for calculation of inter-observer agreement. A
modified Bhalla score13 was applied to determine the type,
presence and severity of 12 radiological abnormalities, six
airway and six interstitial abnormalities (see Appendix 1).
The severity and/or extent of these was assigned a score of
0e 3 (0Z absent, 1Z mild, 2Z moderate, 3Z severe).
For nodules and micro-nodules a scoring system for inter-
stitial changes in occupational disease was used,14 and
recoded into four groups of Bhalla (0e3). If an abnormality
was present, the most frequent score (1, 2 or 3) was
selected.
For bronchiectasis, the severity was expressed as the
broncho-arterial ratio, which is the diameter of the
bronchial lumen divided by the diameter of the adjacent
pulmonary artery. Bronchiectasis was defined as present if
the ratio was equal to or greater than 1.15 Loss of
tapering is one of the diagnostic criteria of bronchiectasis
on spiral scans. Since HRCT does not include the whole
lung volume, loss of tapering was not used as a specific
criterion in this scoring system. Bronchial wall thickening
was expressed as the sum of thickness of the bronchial
wall on both sides of the lumen divided by the diameter
of the adjacent artery. If the ratio was 0.5 or greater, the
bronchial wall was defined as thickened.16 The presence
of mucus plugging and centrilobular nodules, air trapping,
nodules and micro-nodules, linear and/or irregular opac-
ities, consolidations, ground glass opacities, honey-
combing and emphysema was based on established
criteria.17,18 The sum of scores for 10 HRCT abnormalities
(air trapping excluded) was calculated (maximum possible
scoreZ 30).
Statistical methods
The statistical software package (SPSS version 14.0.2) was
used for the analysis. Statistical significance was set at
level of p < 0.05. Relationship between two continuous
variables was tested by Pearson’s or Spearman’s correla-
tions. Analysis of variance with Tukey as a post hoc test
was used to explore the relationship between HRCT scores
(0e3) and pulmonary function. CT scores were recoded to
two groups only, those with and without a given abnor-
mality (0/1). Two sample T-tests or ManneWhitney were
used to compare means or medians of continuous data,
Chi square and Fisher’s test for groups with categorical
data. Multiple linear regression was used to explore the
relationship between recoded HRCT scores (0/1), clinical
and demographic variables and pulmonary function in
combination with the variable selection strategies for
forward and backward selection. The criterion for
introduction and removal of variables was p < 0.05.
Assumptions concerning regressions were satisfactory.
Cohen’s Kappa scores for inter-observer agreement were
calculated.19
Ethics
The study was conducted according to the ethical guide-
lines at our hospital, which comply with the Helsinki
declaration, and was approved by the hospital’s authorised
representative.Results
Patients and demographics
All patients were Caucasians. Median (range) age was 48
(20e78) years. Table 1 shows the frequency of some extra-
pulmonary manifestations, smoking habit, infections,
productive cough and anti-asthmatic medication. At the
time of PFT, median serum level of C-reactive protein (CRP)
was 6 mg/l (range 1e108.0 mg/l), slightly higher than the
reference value (<4 mg/l). The leukocyte count varied
from 1.0 to 14.0  109/l with 21e86% neutrophils and
7e54% lymphocytes. The dosage immunoglobulins ranged
from 0.1 to 2.0 g/kg/4 weeks. Serum IgG level was 8.3
(2.9) g/l, which is within the normal range (5e15 g/l).
HRCT
Only 6% of the patients had completely normal HRCT
images. Table 2 shows that bronchial wall thickening,
bronchiectasis and air trapping were the most frequent
airway abnormalities, found in 68, 57 and 54% of the
patients, respectively. Twenty-six patients (40%) had both
bronchiectasis and bronchial wall thickening. In the
parenchyma, linear and /or irregular opacities and nodules
and micro-nodules were the dominant findings, seen in
more than 50% of the patients. The majority (40%) of the
nodules were small (diameter less than <1.5 mm). In
contrast to these findings, ground glass opacities and
emphysema were seen in only 12% of the patients. The
mean Kappa scores for the dichotomous HRCT abnormali-
ties (score 0 vs. 1 þ 2 þ 3) was 0.51, ranging from 0.28 with
mucus plugging and centrilobular nodules to 0.89 for
emphysema. The Kappa scores for bronchiectasis, bronchial
wall thickening and linear and/or irregular opacities were
0.56, 0.50 and 0.42 respectively. Except for the
Table 2 Distribution of scores on HRCT abnormalities in 65 patients.
HRCT abnormality
Score 0 Score 1 Score 2 Score 3 With
abnormality
%
n n n n
Airways
1 Bronchiectasis;
severity
28 23 7 7 57
2 Bronchial wall
thickening
21 33 8 3 68
3 Bronchiectasis;
extension
28 22 8 7 57
4 Bronchiectasis:
axial distribution
28 1 26 10 57
5 Mucus plugging and
centrilobular nodules
49 11 3 2 25
6 Air trapping
nZ 54
26 21 3 5 54
Interstitium
7 Nodules and
micro-nodules
32 21 10 2 51
8 Linear and/or
irregular
opacities
30 25 3 7 53
9 Consolidation 41 20 3 1 37
10 Ground glass
opacities
53 6 3 3 12
11 Honeycombing 49 3 2 1 9
12 Emphysema 53 6 2 4 12
See Appendix 1 for score-system.
876 S. Gregersen et al.abnormalities mucus plugging and centrilobular nodules
and ground glass opacities, the 95% confidence intervals did
not include zero.
Pulmonary function
Table 3 (column 1) shows that the upper limit of the
confidence intervals for FEV1, VA, DLCO and DLCO/VA were
below 100%, indicating both airway obstruction, restriction
and diffusion impairment in the group as a whole. The
distribution of FEV1 and FEV1/FVC were slightly skewed. In
40% of the patients, the FEV1/FVC ratio was lower than
0.7, usually regarded as the lower limit of normal. VA and
DLCO/VA were lower than 80% of predicted in 30 and 21%
of the patients, respectively. Taken together, the patient
group was characterised by airway obstruction in 40%,
impaired gas diffusion in 21% and ventilatory restriction
in 34%.
Relation between pulmonary function, HRCT
findings and clinical variables
Univariate analysis of variance (ANOVA) showed that FEV1
and/or FEV1/FVC differed significantly between the scores
(0e3) of severity and extension of bronchiectasis, bronchialwall thickening, air trapping and mucus plugging
(pZ < 0.05).
Multiple bivariate analyses after recoding of the CT
scores to binary variables (present/ not present) showed
that the occurrence of mucus plugging, air trapping and
bronchial wall thickening were related to decreased FEV1/
FVC, FEV1 and/or FVC. Bronchial wall thickening was
also significantly associated with a decrease in DLCO and
DLCO/VA, as were the linear and /or irregular opacities,
ground glass opacities, honeycombing and emphysema. As
an example, column 2 and 3, Table 3, show the differences
in pulmonary function between those with and without
bronchial wall thickening and linear and/or irregular
opacities, the two most frequent HRCT abnormalities.
There was no association between the occurrence of
bronchiectasis and any of the pulmonary function variables.
No relationship was found between pulmonary function
and CT findings on one hand, and age, sIgG, CRP, leukocyte
count, smoking habit, productive cough or extrapulmonary
manifestations on the other. In contrast, the occurrence of
more than two respiratory tract infections during the last
year before the PFT, was associated with a decrease in
DLCO and DLCO/VA. Males had lower FEV1/FVC than
females, while females had lower DLCO.
Corrections for multiple analyses were not performed
since the analysis was extended to multiple linear regression
Table 3 Pulmonary function in 65 patients, and comparison between those with and without bronchial wall thickening and
linear and/or irregular opacities.
Pulmonary function Total Bronchial wall thickening Linear and/or
irregular opacities
L (SD) % pred (95% CI) Yes No p Yes No p
% pred % pred % pred % pred
FVC Mean 4.0 (1.2) 99.4 (94.5,104.3) 96.1 106.1 0.019 99.6 99.1 0.910
FEV1 Mean 2.8 (1.0) 85.5 (79.8, 91.7) 80.0 97.9 0.001 85.6 86.0 0.952
FEV1/FVC Mean 70.9
a (13.5) 68.6 75.8 0.043 70.3 71.2 0.852
DLCO Mean 7.8b (2.9) 78.9 (84.2, 92.5) 73.8 90.4 0.005 73.6 85.0 0.039
VA Mean 5.6 (1.6) 88.4 (84.2, 92.5) 86.0 93.6 0.093 88.9 87.8 0.792
DLCO/VA Mean 1.4c (0.4) 89.9 (84.6, 95.1) 86.3 97.8 0.043 82.6 98.1 0.003
L: Liter. %: predZ percent of predicted (ERS 1993 update).
a %.
b mmol/min/kPa.
c mmol/min/kPa/L.
HRCT and lung function in CVID 877(Table 4). HRCTabnormalities with significant relation to the
pulmonary function on bivariate analysis presented in the
previous paragraphs were introduced to the regressions (see
text above and legend, Table 4). As an example of the results
presented in Table 4, the Beta coefficient (B) in line 1 shows
that FEV1% predicted was 17.9 percent points lower in
patient with bronchial wall thickening compared to those
without (pZ 0.004). R square adjusted shows that the
presence of bronchial wall thickening could explain 11% of
the variation in FEV1% predicted. In summary, Table 4 shows
that the presence of bronchial wall thickening was a signifi-
cant determinant of lower FEV1 and DLCO, emphysema was
a determinant for lower FEV1/FVC and DLCO/VA, mucus
plugging related to lower FEV1/FVC, honeycombing to lower
DLCO and the presence of linear and or irregular opacities
was a determinant of lower DLCO/VA. Finally females had
lower DLCO than males and the presence of more than twoTable 4 Determinants of pulmonary function analysed by linea
Dependent
variable
Unit Variable in the equation
FEV1 % pred Bronchial wall thickening
FEV1/FVC % pred Mucus plugging
Emphysema
DLCOc % pred Bronchial wall thickening
Honeycombing
Gender (females)
DLCO/VAc % pred Linear and/or irreg. opacities
Emphysema
>2 infections last year
% predZ percent of predicted (ERS 1993 update). BZ beta coefficie
a Forward and backward regressions gave equal results.
b No regressions performed for FVC and VA, since bivariate analysis g
were introduced to; FEV1: Bronchial wall thickening, mucus plugging
mucus plugging and centrilobular nodules, emphysema, gender. DLCO
irregular opacities, honeycombing, emphysema, gender, ><2 infecti
opacities, emphysema, honeycombing, ><2 infections.
c nZ 63.annual infections was related to lower DLCO/VA. The
differences in time between CT scans and pulmonary func-
tion tests have been controlled for.Excluded patients
Median sum of HRCT scores for the five patient excluded
due to infection was 9 (range 0e18) which was significantly
higher than 5 (range 0e18) for the patients in the study
(pZ 0.018). FVC, FEV1 and VA % predicted were lower in
these five excluded compared to the included (pZ 0.000,
0.035 and 0.003). For the 13 patients excluded due to
lack of HRCT within 13 months from PFT, the means of
the pulmonary function variables were not significantly
different from the 65 patients studied (pZ 0.377e
0.900).r regression in 65 patients with CVID.a b
B 95% CI p R square
adjusted
17.9 30.1, 5.8 0.004 0.11
14.2 20.7, 7.7 0.000 0.30
13.3 20.5, 6.1 0.000
15.3 25.7, 4.9 0.005 0.27
24.2 40.7, 7.7 0.005
13.6 3.9, 23.3 0.007
17.1 26.2, 8.1 0.012 0.27
14.3 26.3, 2.9 0.015
12.2 21.6, 2.8 0.000
nt.
ave no or only on significant association. Variables (binary) which
and centrilobular nodules. FEV1/FVC: Bronchial wall thickening,
: Bronchial wall thickening, ground glass opacities, linear and/or
ons. DLCO/VA: Bronchial wall thickening, linear and/or irregular
Figure 2 HRCT of left lung with linear and/or irregular
opacities.
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In the present study we have shown that airway obstruc-
tion, impaired gas diffusion and ventilatory restriction were
frequent findings in CVID patients. While multivariate
analysis showed no association between bronchiectasis and
impaired pulmonary function, bronchial wall thickening,
seen in two thirds of the patients on HRCT, was a significant
determinant of both FEV1 and DLCO. Moreover, linear and/
or irregular opacities, the most frequent interstitial
abnormality, was a significant determinant of DLCO/VA.
Our estimates of reduced lung function do not differ
from previous reports, since they are higher than in some
studies and lower than in others.3,20,21
Bhalla has developed a quantitative scoring system for
HRCT abnormalities related to bronchiectasis in cystic
fibrosis (CF).13 Other similar quantitative systems are now
common in evaluation of both CF and non-CF related
bronchiectatic diseases.16,22e25 Using a modified Bhalla
system, supplemented with scores for interstitial changes,
we found that HRCT abnormalities were frequent, seen in
more than 90% of the patients. This is in agreement with
a study reported by Kainulainen (96%).20 The border
between normality and abnormality on HRCT is sometimes
unclear, since there are few studies of normality. In addi-
tion, radiological assessment involves an element of
subjectivity. In previous reports similar quantitative scoring
systems for bronchiectasis have been found reliable and
reproducible.22 The Kappa scores for the most important
findings in our study are generally considered as ‘‘moder-
ately good’’,19 indicating that our scoring system is fairly
reliable.
We defined bronchiectasis as present if the broncho-
arterial ratio was equal to or greater than one, while most
previous studies have set the limit at a ratio greater than
one.6,23 Our choice was based on a study of healthy people
in which mean broncho-arterial ratio was 0.7 (range 0.52e
0.94).26 The fact that most changes were mild, supports our
choice of a more sensitive scoring system than the original
Bhalla method.13 Bronchiectasis was a frequent finding, but
not as frequent as reported by Thickett (70%).3 It is note-
worthy that more than 40% of the patients did not have
bronchiectasis. Furthermore, although the few patients
with severe bronchiectasis (score 3) had lower FEV1 than
those with other scores, the presence or absence of bron-
chiectasis was not related to pulmonary function. On the
other hand, even if they are a poor marker of impaired
pulmonary function at an early phase, the importance of
bronchiectasis should not be underestimated, since their
contribution to recurrent and persistent respiratory infec-
tion and inflammation has been well established.2,27
We found, like Gharagozlou,23 that bronchial wall
thickening was more frequent than bronchiectasis, while
others have found the opposite.28 Thickening of the
bronchial wall as a determinant of airflow obstruction has
previously been reported in studies on bronchiectasis in
non-CVID patients,29 but has been given little attention in
the follow up of CVID.3,30 The fact that patients with even
mild bronchial wall thickening (score 1) had lower FEV1
than those with normal wall thickness, underlines the
importance of this abnormality. Bronchial wall thickeningcan probably be regarded as inflammatory changes
extending from the large airways to the periphery,
including the alveoli. This could explain the relationship
to the low DLCO. Whatever the mechanism, data from the
present study suggest that bronchial wall thickening
should be further investigated as an early and reliable
marker of impaired pulmonary function in CVID, not only
as a determinant of reduced FEV1 but also of reduced gas
exchange.
Radiologically, inflammation of the large and small
airways are often visualised as mucus plugging and cen-
trilobular nodules respectively, which might explain why
this abnormality was related to low FEV1/FVC ratio. Air
trapping, usually regarded as a manifestation of small
airway disease, was related to impaired airway function in
the univariate analysis. When it was included in the
multiple regressions, it came out as a significant determi-
nant of obstruction. However, it was not included in the
final regression due to selection and insufficient patient
number.
The term ‘‘linear and/or irregular opacities’’ has not
been used in previous studies of CVID. This abnormality,
seen in more than one half of our patients, appears as
a messy picture of any linear opacity of irregular thickness
which does not respect the lung architecture (Fig. 2). In
previous reports of CVID this feature may has been classi-
fied as interseptal lines, consolidations, fibrosis or scars.
Linear and/or irregular opacities is a well known radiolog-
ical feature of interstitial pneumonias.17 The fact that this
was the most frequent interstitial finding, justifies our
HRCT and lung function in CVID 879choice of including it in the assessment of interstitial
abnormalities. Since it was also a determinant of impaired
gas diffusion, we consider this abnormality to be a key
feature of pulmonary disease in CVID.
The patho-physiological mechanisms leading to abnor-
malities of airways and lung parenchyma in CVID are not
clear. Factors involved in antibacterial defence, chronic
inflammation and autoimmunity as well as genetic factors
probably play a role. For instance, one study has shown that
low levels of mannose binding lectin, a factor of the innate
immunity, were related to increased frequency of lower
respiratory tract infections and bronchiectasis in CVID.31
Previously, we have reported an inverse relationship
between a marker of inflammation, namely circulatory
tumour necrosis alpha, and gas diffusion in a small number
of patients (nZ 36) with CVID.32
High resolution computed tomography has become
a sensitive, easily accessible and fairly standardised method
for detecting abnormalities in lung parenchyma and airways.
On one hand, HRCT probably reflects the visible individual
responses to the various pathogenic factors in CVID. On the
other, HRCT in this study was a visual determinant of lung
function in CVID patients adequately treated with immuno-
globulins. Consequently, HRCT, together with pulmonary
function tests, should remain an important tool in the clin-
ical monitoring of these patients.Appendix 1. Scoring system for HRCT images
HRCT
abnormality
Score 0 Score 1
Airways
1 Bronchiectasis:
severity
Absent >[ 1e<1.5
times diameter
of adjacent arte
2 Bronchial
wall thickening
Absent 0.5e<1 times
diameter of
adjacent artery
3 Bronchiectasis:
extension
Absent 1e5 segments
4 Bronchiectasis:
axial distribution
Absent Central
5 Mucus plugging
and centrilobular
nodules
Absent 1e5 segments
6 Air trapping Absent 1e5 segments
Interstitium
7 Nodules and
micro-nodulesa
Absent Mild (1e6 points)
8 Linear and/or
irregular opacities
Absent 1e3 segments
9 Consolidation Absent 1e3 segments
10 Ground glass
opacities
Absent 1e5 segments
11 Honeycombing Absent 1e5 segments
12 Emphysema Absent 1e5 segments
a Each of the six lobes was given an initial score (point) from 0 to 3. TIn conclusion, in a cross sectional study of 65 adult CVID
patients, we found both airway obstruction, ventilatory
restriction and impaired gas diffusion. Bronchial wall
thickening and linear and/or irregular opacities, probably
reflecting inflammatory changes, were the most frequent
findings on HRCT and were significantly related to impaired
lung function. To determine the impact these abnormalities
might have on the further development of the disease, they
should be included in further studies as well as in the
clinical follow up of patients with CVID.Conflict of interest statement
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ry
1.5e2 times
diameter of
adjacent artery
>2 times diameter of
adjacent artery
1e1.5 times
diameter of
adjacent artery
>1.5 times diameter
of adjacent artery
6e9 segments >9 segments
Peripheral Mixed
6e9 segments >9 segments
6e9 segments >9 segments
Moderate (7e12 points) Severe (13e18 points)
4e6 segments >6 segments
4e6 segments >6 segments
6e9 segments >9 segments
6e9 segments >9 segments
6e9 segments >9 segments
he points (0e18) was then recoded into four groups (scores 0e3).
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